Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial

Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial

Background: A significant proportion of patients with head and neck squamous cell carcinoma (HNSCC) have advanced-stage disease (stages III to IVB) that do not respond to therapy despite aggressive, site-specific multimodality therapy. A great number of them will develop disease recurrence, with up...

Full description

Bibliographic Details
Main Authors: Francesco Perri, Francesco Longo, Roberta Fusco, Valeria D’Alessio, Corrado Aversa, Ettore Pavone, Monica Pontone, Maria Luisa Marciano, Salvatore Villano, Pierluigi Franco, Giulia Togo, Gianluca Renato De Fazio, Daniele Ordano, Fabio Maglitto, Giovanni Salzano, Maria Grazia Maglione, Agostino Guida, Franco Ionna
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
electrochemotherapy
recurrent cell squamous carcinoma
randomized trial
Online Access:https://www.mdpi.com/2072-6694/13/9/2210

Internet

https://www.mdpi.com/2072-6694/13/9/2210

Similar Items